These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33333252)

  • 41. What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak.
    Mehta M; Purpura LJ; McConville TH; Neidell MJ; Anderson MR; Bernstein EJ; Dietz DE; Laracy J; Gunaratne SH; Miller EH; Cheng J; Zucker J; Shah SS; Chaudhuri S; Gordillo CA; Patel SR; Guo TW; Karaaslan LE; Reshef R; Miko BA; Bathon JM; Pereira MR; Uhlemann AC; Yin MT; Sobieszczyk ME
    PLoS One; 2021; 16(4):e0249349. PubMed ID: 33831046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections.
    Minihan B; McAuliffe E; Powell J; Wong SL; Wilkie K; Murphy C; Maher A; Power L; O'Connell NH; Dunne CP
    J Hosp Infect; 2022 Aug; 126():29-36. PubMed ID: 35472487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity.
    Troyer BS; Kovacic Scherrer N; Garavaglia J
    J Pharm Pract; 2024 Jun; 37(3):632-636. PubMed ID: 36803310
    [No Abstract]   [Full Text] [Related]  

  • 44. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
    de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
    Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
    Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
    PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
    Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B
    J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
    Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
    J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes Among Mechanically Ventilated Patients With Severe Pneumonia and Acute Hypoxemic Respiratory Failure From SARS-CoV-2 and Other Etiologies.
    Nolley EP; Sahetya SK; Hochberg CH; Hossen S; Hager DN; Brower RG; Stuart EA; Checkley W
    JAMA Netw Open; 2023 Jan; 6(1):e2250401. PubMed ID: 36626168
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of the effectiveness of tocilizumab on mortality and progression to mechanical ventilation or intensive care in patients with COVID-19 admitted to a tertiary hospital.
    Pinilla Rello A; Magallón Martínez A; Vicente Iturbe C; Escolano-Pueyo A; Herranz Bayo E; Aguilo Lafarga I
    Eur J Hosp Pharm; 2024 Apr; 31(3):212-219. PubMed ID: 36150845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).
    Rodríguez-Baño J; Pachón J; Carratalà J; Ryan P; Jarrín I; Yllescas M; Arribas JR; Berenguer J; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    Clin Microbiol Infect; 2021 Feb; 27(2):244-252. PubMed ID: 32860964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.
    Russo G; Solimini A; Zuccalà P; Zingaropoli MA; Carraro A; Pasculli P; Perri V; Marocco R; Kertusha B; Del Borgo C; Del Giudice E; Fondaco L; Tieghi T; D'Agostino C; Oliva A; Vullo V; Ciardi MR; Mastroianni CM; Lichtner M
    PLoS One; 2021; 16(9):e0257376. PubMed ID: 34506608
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
    Veiga VC; Prats JAGG; Farias DLC; Rosa RG; Dourado LK; Zampieri FG; Machado FR; Lopes RD; Berwanger O; Azevedo LCP; Avezum Á; Lisboa TC; Rojas SSO; Coelho JC; Leite RT; Carvalho JC; Andrade LEC; Sandes AF; Pintão MCT; Castro CG; Santos SV; de Almeida TML; Costa AN; Gebara OCE; de Freitas FGR; Pacheco ES; Machado DJB; Martin J; Conceição FG; Siqueira SRR; Damiani LP; Ishihara LM; Schneider D; de Souza D; Cavalcanti AB; Scheinberg P;
    BMJ; 2021 Jan; 372():n84. PubMed ID: 33472855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
    Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
    JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. "Ventilator-free days" composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis.
    Mady AF; Abdulrahman B; Mumtaz SA; Al-Odat MA; Kuhail A; Altoraifi R; Alshae R; Alharthy AM; Aletreby WT
    Heart Lung; 2022; 56():118-124. PubMed ID: 35839546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia.
    Papamanoli A; Kalogeropoulos AP; Hotelling J; Yoo J; Grewal P; Predun W; Jacob RP; Cao K; Marcos LA; Skopicki HA
    JAMA Netw Open; 2021 Oct; 4(10):e2127172. PubMed ID: 34605919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.
    Ringer M; Azmy V; Kaman K; Tang D; Cheung H; Azar MM; Price C; Malinis M
    Transpl Infect Dis; 2021 Apr; 23(2):e13556. PubMed ID: 33378571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
    Salama C; Han J; Yau L; Reiss WG; Kramer B; Neidhart JD; Criner GJ; Kaplan-Lewis E; Baden R; Pandit L; Cameron ML; Garcia-Diaz J; Chávez V; Mekebeb-Reuter M; Lima de Menezes F; Shah R; González-Lara MF; Assman B; Freedman J; Mohan SV
    N Engl J Med; 2021 Jan; 384(1):20-30. PubMed ID: 33332779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tocilizumab for COVID-19 treatment. An Argentine report.
    Galvalisi N; Pagotto VL; Tudanca V; Allalla F; Ferraro H; Santamarina J; Schejtman A; Rotryng F
    Medicina (B Aires); 2022; 82(1):13-20. PubMed ID: 35037856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.